- Report
- October 2023
- 190 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Clinical Trials
- April 2024
- 110 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,245GBP
- Report
- May 2021
- 48 Pages
Global
From €3358EUR$3,495USD£2,871GBP
- Clinical Trials
- December 2019
- 383 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Drug Pipelines
- September 2020
- 1216 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- May 2022
- 600 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Report
- November 2023
- 178 Pages
Global
From €2689EUR$2,799USD£2,299GBP
Malignant Mesothelioma is a rare form of cancer that affects the lining of the lungs, abdomen, and heart. It is caused by exposure to asbestos and is difficult to treat. Oncology drugs are used to treat this type of cancer, and the Malignant Mesothelioma Drug market is a subset of the larger Oncology Drug market.
The Malignant Mesothelioma Drug market is composed of a variety of drugs, including chemotherapy, immunotherapy, and targeted therapy. These drugs are used to treat the cancer, reduce symptoms, and improve quality of life. The drugs are typically administered in combination with other treatments, such as surgery and radiation therapy.
The Malignant Mesothelioma Drug market is highly competitive, with many companies developing and marketing drugs for this type of cancer. Some of the companies in the market include Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Novartis. Show Less Read more
